<DOC>
	<DOCNO>NCT01726309</DOCNO>
	<brief_summary>Primary Objective : Correlation skin and/or eye toxicity grade secondary Cetuximab Panitumumab SNP profile Epidermal Growth Factor Receptor ( EGFR ) domain III region . Secondary Objectives : Correlation SNP profile indicator tumour response parameter , radiological response , duration response , time progression ( TTP ) , overall survival ( OS ) time , incidence non-dermatological adverse event .</brief_summary>
	<brief_title>Single Nucleotide Polymorphism ( SNP ) Study . ICORG 08-40 , V4</brief_title>
	<detailed_description>Baseline assessment : - Contact Lenses - Medical History - Previous chemotherapy - Vital Signs ( weight , height , Karnofsky Performance status , heart rate , blood pressure ) - Symptom Assessment ( Pre-existing skin and/or eye condition , CEA measurement ( CRC ) , Disease status ( TNM Staging ) ) - Planned chemotherapy regimen - Radiotherapy Blood Sample : A 2ml blood sample collect ethylenediamine-tetraacetic acid ( EDTA ) contain Vacutainer time start treatment . DNA extract sample 11 SNPs region EGFR gene encode domain III characterize . Follow-up Assessment : every second cycle Cetuximab- Panitumumab-containing regimen ( CRC : every 2 . Week ; NSCLC : every 3-4 week ) : - Visit Number Date - Vital Signs ( weight , height , Karnofsky Performance status , heart rate , blood pressure ) - Symptom Assessment ( CEA measurement ( CRC ) , Disease status ( TMN Staging ) , Skin Toxicity ( CTCAE ) grade ) - Current chemotherapy regimen - Radiotherapy - CEA measurement CRC ( every second cycle/every 4 week ) Long-term follow-up ( 5 year ) : - CT restaging ( TNM Staging ) do 3 monthly long subject receive Cetuximab- Panitumumab- contain regimen suspicion disease progression . - OS</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Stage IV ( AJCC 7th Edition TMN Staging , Appendix C ) , histologically confirm CRC wildtype KRAS candidate metastasectomy . 2 . Stage IV ( AJCC 7th Edition , TMN Staging , Appendix C ) NSCLC express EGFR ( IHC test ) 3 . Patients , receive treatment EGFRantibody ( Cetuximab Panitumumab ) . 4 . Karnofsky performance status ( Appendix B ) score ≥60 . 5 . Acceptable laboratory value : Haemoglobin ≥ 9 g/dL . Neutrophil count ≥ 1.0 x 10^9/L . Platelet count ≥100 x 10^9/L . Serum creatinine ≤1.5 time upper limit normal . Bilirubin ≤1.5 time upper limit normal . Aspartate aminotransferase alanine aminotransferase ≤5 time upper limit normal . 1 . Aged &lt; 18 year 2 . Prior exposure Cetuximab Panitumumab 3 . The CRC carry wildtype KRAS . 4 . The NSCLC stain negative EGFR protein expression 5 . Second cancer diagnosis ( apart nonmelanoma skin cancer ) 6 . Known hypersensitivity Cetuximab Panitumumab , murine protein . 7 . Known history coronary artery disease , arrhythmia , congestive heart failure ( If treat physician feel patient 's coronary artery disease / arrhythmia / congestive heart failure place him/her risk treatment antiEGFR antibody , person include . This clinical decision , make treat physician ) . 8 . Known pregnant ( pregnancy test mandatory ) breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>